FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2484509938> ?p ?o ?g. }

• W2484509938 abstract "Background The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether insulin secretagogues (sulphonylureas and meglitinide analogues) are able to prevent or delay T2DM and its associated complications in people at risk for the development of T2DM is unknown. Objectives To assess the effects of insulin secretagogues on the prevention or delay of T2DM and its associated complications in people with impaired glucose tolerance, impaired fasting blood glucose, moderately elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these. Search methods We searched the Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform, and the reference lists of systematic reviews, articles and health technology assessment reports. We asked investigators of the included trials for information about additional trials. The date of the last search of all databases was April 2016. Selection criteria We included randomised controlled trials (RCTs) with a duration of 12 weeks or more comparing insulin secretagogues with any pharmacological glucose‐lowering intervention, behaviour‐changing intervention, placebo or no intervention in people with impaired fasting glucose, impaired glucose tolerance, moderately elevated HbA1c or combinations of these. Data collection and analysis Two review authors read all abstracts and full‐text articles/records, assessed quality and extracted outcome data independently. One review author extracted data which were checked by a second review author. We resolved discrepancies by consensus or the involvement of a third review author. For meta‐analyses we used a random‐effects model with investigation of risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We carried out trial sequential analyses (TSAs) for all outcomes that could be meta‐analysed. We assessed the overall quality of the evidence by using the GRADE instrument. Main results We included six RCTs with 10,018 participants; 4791 participants with data on allocation to intervention groups were randomised to a second‐ or third‐generation sulphonylurea or a meglitinide analogue as monotherapy and 29 participants were randomised to a second‐generation sulphonylurea plus metformin. Three trials investigated a second‐generation sulphonylurea, two trials investigated a third‐generation sulphonylurea and one trial a meglitinide analogue. A total of 4873 participants with data on allocation to control groups were randomised to a comparator group; 4820 participants were randomised to placebo, 23 to diet and exercise, and 30 participants to metformin monotherapy. One RCT of nateglinide contributed 95% of all participants. The duration of the intervention varied from six months to five years. We judged none of the included trials as at low risk of bias for all 'Risk of bias' domains. All‐cause and cardiovascular mortality following sulphonylurea (glimepiride) treatment were rarely observed (very low‐quality evidence). The RR for incidence of T2DM comparing glimepiride monotherapy with placebo was 0.75; 95% CI 0.54 to 1.04; P = 0.08; 2 trials; 307 participants; very low‐quality evidence. One of the trials reporting on the incidence of T2DM did not define the diagnostic criteria used. The other trial diagnosed T2DM as two consecutive fasting blood glucose values ≥ 6.1 mmol/L. TSA showed that only 4.5% of the diversity‐adjusted required information size was accrued so far. No trial reported data on serious adverse events, non‐fatal myocardial infarction (MI), non‐fatal stroke, congestive heart failure (HF), health‐related quality of life or socioeconomic effects. One trial with a follow‐up of five years compared a meglitinide analogue (nateglinide) with placebo. A total of 310/4645 (6.7%) participants allocated to nateglinide died compared with 312/4661 (6.7%) participants allocated to placebo (hazard ratio (HR) 1.00; 95% CI 0.85 to 1.17; P = 0.98; moderate‐quality evidence). The two main criteria for diagnosing T2DM were a fasting plasma glucose level ≥ 7.0 mmol/L or a 2‐hour post challenge glucose ≥ 11.1 mmol/L. T2DM developed in 1674/4645 (36.0%) participants in the nateglinide group and in 1580/4661 (33.9%) in the placebo group (HR 1.07; 95% CI 1.00 to 1.15; P = 0.05; moderate‐quality evidence). One or more serious adverse event was reported in 2066/4602 (44.9%) participants allocated to nateglinide compared with 2089/4599 (45.6%) participants allocated to placebo. A total of 126/4645 (2.7%) participants allocated to nateglinide died because of cardiovascular disease compared with 118/4661 (2.5%) participants allocated to placebo (HR 1.07; 95% CI 0.83 to 1.38; P = 0.60; moderate‐quality evidence). Comparing participants receiving nateglinide with those receiving placebo for the outcomes MI, non‐fatal stroke and HF gave the following event rates: MI 116/4645 (2.5%) versus 122/4661 (2.6%), stroke 100/4645 (2.2%) versus 110/4661 (2.4%) and numbers hospitalised for HF 85/4645 (1.8%) versus 100/4661 (2.1%) ‐ (HR 0.85; 95% CI 0.64 to 1.14; P = 0.27). The quality of the evidence was moderate for all these outcomes. Health‐related quality of life or socioeconomic effects were not reported. Authors' conclusions There is insufficient evidence to demonstrate whether insulin secretagogues compared mainly with placebo reduce the risk of developing T2DM and its associated complications in people at increased risk for the development of T2DM. Most trials did not investigate patient‐important outcomes." @default.
• W2484509938 created "2016-08-23" @default.
• W2484509938 creator A5010290599 @default.
• W2484509938 creator A5025682200 @default.
• W2484509938 creator A5067087314 @default.
• W2484509938 creator A5068479225 @default.
• W2484509938 date "2016-10-17" @default.
• W2484509938 modified "2023-10-17" @default.
• W2484509938 title "Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus" @default.
• W2484509938 cites W119107369 @default.
• W2484509938 cites W1511593276 @default.
• W2484509938 cites W1532542861 @default.
• W2484509938 cites W157267557 @default.
• W2484509938 cites W1604800572 @default.
• W2484509938 cites W177110716 @default.
• W2484509938 cites W1853587219 @default.
• W2484509938 cites W1855278889 @default.
• W2484509938 cites W1858763784 @default.
• W2484509938 cites W1926884931 @default.
• W2484509938 cites W1965055157 @default.
• W2484509938 cites W1965146429 @default.
• W2484509938 cites W1967140460 @default.
• W2484509938 cites W1968893175 @default.
• W2484509938 cites W1969550954 @default.
• W2484509938 cites W1971441597 @default.
• W2484509938 cites W1973914781 @default.
• W2484509938 cites W1978314817 @default.
• W2484509938 cites W1983130632 @default.
• W2484509938 cites W1983868975 @default.
• W2484509938 cites W1986452741 @default.
• W2484509938 cites W1986686095 @default.
• W2484509938 cites W1994768261 @default.
• W2484509938 cites W1996470340 @default.
• W2484509938 cites W1996837349 @default.
• W2484509938 cites W1998003309 @default.
• W2484509938 cites W2006175454 @default.
• W2484509938 cites W2006836104 @default.
• W2484509938 cites W2009064318 @default.
• W2484509938 cites W2010825674 @default.
• W2484509938 cites W2011172716 @default.
• W2484509938 cites W2019934596 @default.
• W2484509938 cites W2020480331 @default.
• W2484509938 cites W2020486635 @default.
• W2484509938 cites W2020556724 @default.
• W2484509938 cites W2022075825 @default.
• W2484509938 cites W2022936635 @default.
• W2484509938 cites W2026531287 @default.
• W2484509938 cites W2028834965 @default.
• W2484509938 cites W2029148695 @default.
• W2484509938 cites W2035330998 @default.
• W2484509938 cites W2036560757 @default.
• W2484509938 cites W2046391772 @default.
• W2484509938 cites W2046830335 @default.
• W2484509938 cites W2047417045 @default.
• W2484509938 cites W2049283578 @default.
• W2484509938 cites W2057397568 @default.
• W2484509938 cites W2064420669 @default.
• W2484509938 cites W2068462874 @default.
• W2484509938 cites W2077994345 @default.
• W2484509938 cites W2080169952 @default.
• W2484509938 cites W2081276121 @default.
• W2484509938 cites W2083901711 @default.
• W2484509938 cites W2086385008 @default.
• W2484509938 cites W2089237254 @default.
• W2484509938 cites W2098923148 @default.
• W2484509938 cites W2099304231 @default.
• W2484509938 cites W2099466477 @default.
• W2484509938 cites W2104634108 @default.
• W2484509938 cites W2108116635 @default.
• W2484509938 cites W2109146014 @default.
• W2484509938 cites W2119605658 @default.
• W2484509938 cites W2125043520 @default.
• W2484509938 cites W2125435699 @default.
• W2484509938 cites W2125873738 @default.
• W2484509938 cites W2126930838 @default.
• W2484509938 cites W2129241702 @default.
• W2484509938 cites W2131330057 @default.
• W2484509938 cites W2134293572 @default.
• W2484509938 cites W2135098417 @default.
• W2484509938 cites W2137883196 @default.
• W2484509938 cites W2138188443 @default.
• W2484509938 cites W2141028266 @default.
• W2484509938 cites W2141537593 @default.
• W2484509938 cites W2150180487 @default.
• W2484509938 cites W2154717294 @default.
• W2484509938 cites W2155155546 @default.
• W2484509938 cites W2158822657 @default.
• W2484509938 cites W2160565799 @default.
• W2484509938 cites W2160795579 @default.
• W2484509938 cites W2167888541 @default.
• W2484509938 cites W2171111655 @default.
• W2484509938 cites W2188846692 @default.
• W2484509938 cites W2294939922 @default.
• W2484509938 cites W2332951586 @default.
• W2484509938 cites W2337454357 @default.
• W2484509938 cites W2611127318 @default.
• W2484509938 cites W2616009730 @default.
• W2484509938 cites W3022903699 @default.
• W2484509938 cites W4211062734 @default.
• W2484509938 cites W4213055016 @default.

• next